Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Veru Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
VERU
Nasdaq
2834
https://verupharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Veru Inc
What Makes Veru (VERU) a New Buy Stock
- Apr 17th, 2024 4:00 pm
Veru Announces Date of 2024 Annual Meeting of Shareholders
- Apr 1st, 2024 8:05 pm
Veru Reschedules Annual Meeting of Shareholders
- Mar 22nd, 2024 8:05 pm
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
- Mar 12th, 2024 12:00 pm
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
- Feb 28th, 2024 12:15 am
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
- Feb 20th, 2024 1:30 pm
After Plunging -15.61% in 4 Weeks, Here's Why the Trend Might Reverse for Veru Inc. (VERU)
- Feb 13th, 2024 2:35 pm
Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript
- Feb 9th, 2024 3:46 pm
Q1 2024 Veru Inc Earnings Call
- Feb 9th, 2024 3:19 am
Veru Reports Fiscal 2024 First Quarter Financial Highlights
- Feb 8th, 2024 11:30 am
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
- Feb 6th, 2024 1:30 pm
Charles River (CRL) to Report Q4 Earnings: What's in Store?
- Feb 1st, 2024 3:08 pm
Veru Inc. (VERU) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
- Feb 1st, 2024 3:00 pm
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Jan 31st, 2024 1:30 pm
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
- Jan 25th, 2024 1:30 pm
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
- Jan 8th, 2024 1:30 pm
Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs
- Dec 19th, 2023 1:30 pm
The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 29%
- Dec 18th, 2023 11:44 am
Veru Announces Pricing of Public Offering of Common Stock
- Dec 14th, 2023 2:00 pm
Veru Announces Proposed Public Offering of Common Stock
- Dec 13th, 2023 9:01 pm
Scroll